Sugi Predict

Sugi Predict / Compounds / SCHEMBL2433730

SCHEMBL2433730

SCHEMBL2433730

COC(=O)Nc1cc(Oc2ccc3c(C(=O)Nc4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)cncc3c2)ncn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.57
▸ ABL1 P00519 5/20 0.57
▸ HCK P08631 6/20 0.55
▸ MKNK2 Q9HBH9 3/20 0.55
▸ FGFR1 P11362 3/20 0.55
▸ KIT P10721 3/20 0.55
▸ MKNK1 Q9BUB5 2/20 0.55
▸ CDK2 P24941 2/20 0.55
▸ CDK8 P49336 2/20 0.55
▸ RET P07949 2/20 0.55
▸ MAP3K7 O43318 2/20 0.55
▸ FES P07332 2/20 0.55
▸ FER P16591 2/20 0.55
▸ MAP4K2 Q12851 2/20 0.55
▸ MAPK14 Q16539 2/20 0.55
▸ STK25 O00506 1/20 0.55
▸ CIT O14578 1/20 0.55
▸ MAP2K7 O14733 1/20 0.55
▸ IKBKB O14920 1/20 0.55
▸ AURKA O14965 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435870 0.94 ABL1 (0.57) SRCABL1HCKMKNK2FGFR1
SCHEMBL2433262 0.92 SRC (0.59) SRCABL1HCKMKNK2FGFR1
SCHEMBL2435727 0.91 KDR (0.56) SRCABL1HCKMKNK2FGFR1
SCHEMBL2434212 0.90 SRC (0.59) SRCABL1HCKMKNK2FGFR1
SCHEMBL2434003 0.87 HCK (0.55) SRCABL1HCKMKNK2FGFR1
SCHEMBL30151207 0.85 KDR (0.57) SRCABL1HCKMKNK2FGFR1
SCHEMBL2434456 0.85 KDR (0.57) SRCABL1HCKMKNK2FGFR1
SCHEMBL2434611 0.84 KDR (0.53) SRCABL1HCKMKNK2FGFR1
SCHEMBL2435234 0.84 KDR (0.55) SRCABL1HCKMKNK2FGFR1
SCHEMBL275088 0.83 HCK (0.60) SRCABL1HCKMKNK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US claimed
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor NOVARTIS AG (CH) 2012-07-05 — — US disclosed
EP-1945217-B1 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2012-05-02 — — EP disclosed
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US disclosed
US-8026247-B2 Bicyclic amides as kinase inhibitors NOVARTIS AG (CH) 2011-09-27 — — US disclosed
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor NOVARTIS AG 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor KDR, FLT4, FLT1 SRC 444/4885ABL1 434/4885HCK 3634/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 SRC 353/4885ABL1 67/4885HCK 439/4885
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor KDR, FLT4, FLT1 SRC 444/4885ABL1 434/4885HCK 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.